Prognostic factors for low-grade astrocytomas have been proposed, but optimal treatment remains controversial. Eighty-eight consecutive adult patients with supratentorial low-grade astrocytomas were retrospectively reviewed to determine specific factors influencing outcome. All underwent craniotomy (43 radical resections, 45 nonradical resections). Sex, age at diagnosis, preoperative Karnofsky performance status (KPS), tumor location, estimated extent of resection, radiation, chemotherapy, histological type, p53 status, MIB-1 staining and the apoptotic index were assessed as parameters for prognostic significance. KPS (p = 0.03), tumor location (p < 0.001), extent of surgical resection (p < 0.001) and radiotherapy (p = 0.01) were significantly assoicated with longer survival rates by univariate analysis. Multivariate analysis also showed a significant correlation between radiation therapy after surgical removal and survival time (p < 0.001). p53 status was not of importance in determining the necessity for radiotherapy. Radical surgical removal is the most important factor in the management of low-grade astrocytomas. Radiation therapy appears to be effective in improving the prognosis regardless of the extent of surgical resection or the p53 status.

Keywords:
Astrocytoma, low-grade, Radiation, p53, Prognosis, Survival, Radical surgery
1.
Ciric I, Ammirati M, Vick N, Mikhael M: Supratentorial gliomas: Surgical considerations and immediate postoperative results. Gross total resection versus partial resection. Neurosurgery 1987;21:21–26.
2.
Forsyth PA, Shaw EG, Scheithauer BW, O’Fallon JR, Layton DD, Katzmann J: Supratentorial pilocytic astrocytomas. Cancer 1993;72:1335–1342.
3.
Garcia DM, Fulling KH, Marks JE: The value of radiation therapy in addition to surgery for astrocytomas of the adult cerebrum. Cancer 1985;55:919–927.
4.
Janny P, Cure H, Mohr M, Heldt N, Kwiatkowski F, Lemaire JJ, Plagne R, Rozan R: Low grade supratentorial astrocytomas. Management and prognostic factors. Cancer 1994;73:1937–1945.
5.
Kreth FW, Faist M, Rossner R, Volk B, Ostertag C: Supratentorial World Health Organization grade 2 astrocytomas and oligoastrocytomas. Cancer 1996;79:370–379.
6.
Krouwer HG, Davis RL, Silver P, Prados M: Gemistocytic astrocytomas: A reappraisal. J Neurosurg 1991;74:399–406.
7.
Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, MacDonald D, Cairncross G: Supratentorial low-grade glioma in adults: An analysis of prognostic factors and timing of radiation. J Clin Oncol 1997;15:1294–1301.
8.
Lote K, Egeland T, Hager B, Stenwig B, Skullerud K, Berg-Johnsen J, Storm-Mathisen I, Hirschberg H: Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: A retrospective study in 379 patients. J Clin Oncol 1997;15:3129–3140.
9.
Lunsford LD, Somaza S, Kondziolka D, Flickinger JC: Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilocytic astrocytoma. J Neurosurg 1995;82:523–529.
10.
McCormack BM, Miller DC, Budzilovich GN, Voorhees GJ, Ransohoff J: Treatment and survival of low-grade astrocytoma in adults – 1977–1988. Neurosurgery 1992;31:636–642.
11.
Miralbell R, Balart J, Matias G, Molet J, Ariza A, Craven-Bartle J: Radiotherapy for supratentorial low-grade gliomas: Results and prognostic factors with special focus on tumour volume parameters. Radiother Oncol 1993;27:112–116.
12.
North CA, North RB, Epstein JA, Piantadosi S, Wharam MD: Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy. Cancer 1990;66:6–14.
13.
Piepmeier J, Christopher S, Spencer D, Byrne T, Kim J, Knisel JP, Lacy J, Tsukerman L, Makuch R: Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 1996;38:872–878.
14.
Shaw EG, Daumas-Duport C, Scheithauer BW, Gilbertson DT, O’Fallon JR, Earle JD, Laws ER Jr, Okazaki H: Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 1989;70:853–861.
15.
Shibamoto Y, Kitakabu Y, Takahashi M, Yamashita J, Oda Y, Kikuchi H, Abe M: Supratentorial low-grade astrocytoma: Correlation of computed tomography findings with effects of radiation therapy and prognostic variables. Cancer 1993;72:190–195.
16.
Soffietti R, ChiÒ A, Giordana MT, Vasario E, Schiffer D: Prognostic factors in well-differentiated cerebral astrocytomas in the adult. Neurosurgery 1989;24:686–692.
17.
Vigliani MC, Sichez N, Poisson M, Delatire JY: A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int J Radiat Oncol 1996;35:527–533.
18.
Hsu DW, Louis DN, Efird JT, Hedley-Whyte ET: Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol 1997;56:857–865.
19.
Nakamura M, Konishi N, Hiasa Y, Tsunoda S, Fukushima Y, Tsuzuki T, Takemura K, Aoki H, Kobitsu K, Sakaki T: Immunohistochemical detection of CDKN2, retinoblastoma and p53 gene products in primary astrocytic tumors. Int J Oncol 1996;8:889–893.
20.
Nakamura M, Konishi N, Tsunoda S, Hiasa Y, Tsuzuki T, Inui T, Sakaki T: Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma. Cancer 1997;80:242–249.
21.
Willet CW, Warland G, Cheek R, Coen J, Efrid J, Schellito PC, Compton CC: Proliferating cell nuclear antigen and mitotic activity in rectal cancer: Predictor of response to preoperative irradiation. J Clin Oncol 1994;12:679–682.
22.
Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T: p53 dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994;78:703–711.
23.
Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456–1462.
24.
Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957–967.
25.
Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR: p53 mutations does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993;53:3667–3669.
26.
Hawkins DS, Demers GW, Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996;56:892–898.
27.
Kyritsis AP, Xu R, Bondy ML, Levin VA, Bruner JM: Correlation of p53 immunoreactivity and sequencing in patients with glioma. Mol Carcinog 1996;15:1–4.
28.
Lee JM, Bernstein A: p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993;90:5742–5746.
29.
Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807–810.
30.
Aoki H, Ohnishi K, Wang X, Takahashi A, Ohnishi T, Nakamura M, Sakaki T: p53-independent WAF1 induction by ACNU in human glioblastoma cells. Mol Carcinog 1998;21:171–176.
31.
Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 1992;355:846–847.
32.
Tsuzuki T, Tsunoda S, Sakaki T, Konishi N, Hiasa Y, Nakamura M: Alterations of RB, p53, p16 (CDKN2), and p15 genes in human astrocytomas. Cancer 1996;78:287–293.
33.
Kleihues P, Burger PC, Scheithauer BW: Histological typing of tumours of the central nervous system. Berlin, Springer, 1993.
34.
Cattoretti G, Becker MH, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-363.
35.
Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493–501.
36.
Fadul C, Wood J, Thaler H, Galicich J, Patterson RH Jr, Posner JB: Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology 1988;38:1374–1379.
37.
Shapiro WR: Treatment of neuroectodermal brain tumors. Ann Neurol 1982;12:231–237.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.